Literature DB >> 19442530

Quality of life of grown-up congenital heart disease patients after congenital cardiac surgery.

Ophélie Loup1, Catherina von Weissenfluh, Brigitta Gahl, Markus Schwerzmann, Thierry Carrel, Alexander Kadner.   

Abstract

BACKGROUND: Due to better early and long-term outcome, the increasing population of grown-ups with congenital heart disease (GUCH) brings up unexpected quality of life (QoL) issues. The cardiac lesion by itself is not always the major problem for these patients, since issues pertaining to QoL and psychosocial aspects often predominate. This study analyses the QoL of GUCH patients after cardiac surgery and the possible impact of medical and psychosocial complications. PATIENTS AND METHODS: A questionnaire package containing the SF-36 health survey (health related QoL), the HADS test (anxiety/depression aspects) and an additional disease specific questionnaire was sent to 345 patients (mean 26+/-11 years) operated for isolated transposition of the great arteries (TGA), tetralogy of Fallot (TOF), and ventricular septal defect (VSD). The scores were compared with age- and gender-matched standard population data and in relation to the underlying congenital heart disease (CHD).
RESULTS: In all SF-36 and HADS health dimensions the GUCH patients showed excellent scores (116+/-20), which are comparable to the standard population (100+/-15), regardless of the initial CHD (p=0.12). Eighty-two percent of the patients were found to be in NYHA class I and 83% patients declared that they do not consider their QoL to be limited by their malformation. Complications like reoperations (p=0.21) and arrhythmias (p=0.10) do not show significant impact on the QoL. The additional questionnaire revealed that 76% of adult patients have a fulltime job, 18% receive a full or partial disability pension, 21% reported problems with insurances, most of them regarding health insurances (67%), and 4.4% of adult patients declared to have renounced the idea of having children due to their cardiac malformation.
CONCLUSION: QoL in GUCH patients following surgical repair of isolated TOF, TGA and VSD is excellent and comparable to standard population, this without significant difference between the diagnosis groups. However, these patients are exposed to a high rate of complications and special psychosocial problems, which are not assessed by standardized questionnaires, such as the SF-36 and HADS. These findings highlight the great importance for a multidisciplinary and specialized follow-up for an adequate management of these complex patients.

Entities:  

Mesh:

Year:  2009        PMID: 19442530     DOI: 10.1016/j.ejcts.2009.03.023

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

Review 1.  Health-related quality of life in adults with tetralogy of Fallot repair: a systematic review and meta-analysis.

Authors:  Mahim Malik; Zaiba Shafik Dawood; Mahin Janjua; Sardar Shahmir Babar Chauhan; Laila Akbar Ladak
Journal:  Qual Life Res       Date:  2021-05-22       Impact factor: 4.147

2.  Clinical Profile and Quality of Life of Adult Patients After the Fontan Procedure.

Authors:  Giulia Bordin; Massimo Antonio Padalino; Sonja Perentaler; Biagio Castaldi; Nicola Maschietto; Pierantonio Michieli; Roberto Crepaz; Anna Chiara Frigo; Vladimiro Lorenzo Vida; Ornella Milanesi
Journal:  Pediatr Cardiol       Date:  2015-04-02       Impact factor: 1.655

Review 3.  Emotional functioning of adolescents and adults with congenital heart disease: a meta-analysis.

Authors:  Jamie L Jackson; Brian Misiti; Jeffrey A Bridge; Curt J Daniels; Kathryn Vannatta
Journal:  Congenit Heart Dis       Date:  2014-02-26       Impact factor: 2.007

4.  Quality of life experienced by adolescents and young adults with congenital heart disease.

Authors:  Flávio Miguel Teixeira; Rosália Maria Coelho; Cidália Proença; Ana Margarida Silva; Daniela Vieira; Cláudia Vaz; Cláudia Moura; Victor Viana; José Carlos Areias; Maria Emília Guimarães Areias
Journal:  Pediatr Cardiol       Date:  2011-06-28       Impact factor: 1.655

5.  Psychosocial functioning of adults with congenital heart disease: outcomes of a 30-43 year longitudinal follow-up.

Authors:  Petra Opić; Jolien W Roos-Hesselink; Judith A A Cuypers; Maarten Witsenburg; Annemien van den Bosch; Ron T van Domburg; Ad J J C Bogers; Elisabeth M W J Utens
Journal:  Clin Res Cardiol       Date:  2014-12-07       Impact factor: 5.460

6.  Prosthetic valves in adult patients with congenital heart disease: Rationale and design of the Dutch PROSTAVA study.

Authors:  H G Freling; Y J van Slooten; J P van Melle; B J M Mulder; A P J van Dijk; H L Hillege; M C Post; G Tj Sieswerda; M R M Jongbloed; T P Willems; P G Pieper
Journal:  Neth Heart J       Date:  2012-10       Impact factor: 2.380

7.  Health-related quality of life compared with cardiopulmonary exercise testing at the midterm follow-up visit after tetralogy of Fallot repair: a study of the German competence network for congenital heart defects.

Authors:  Goetz C Mueller; Samir Sarikouch; Philipp Beerbaum; Alfred Hager; Karl-Otto Dubowy; Brigitte Peters; Thomas S Mir
Journal:  Pediatr Cardiol       Date:  2012-12-20       Impact factor: 1.655

8.  Long term psychosocial outcomes of congenital heart disease (CHD) in adolescents and young adults.

Authors:  Maria Emília Guimarães Areias; Catarina I Pinto; Patrícia F Vieira; Flávio Teixeira; Rosália Coelho; Isabela Freitas; Samantha Matos; Marta Castro; Sofia Sarmento; Victor Viana; Jorge Quintas; José C Areias
Journal:  Transl Pediatr       Date:  2013-07

9.  Managing the morbidity associated with respiratory viral infections in children with congenital heart disease.

Authors:  Joseph M Geskey; Stephen E Cyran
Journal:  Int J Pediatr       Date:  2012-02-29

10.  Perceived health after percutaneous pulmonary valve implantation: in-depth interviews of patients and next-of-kin.

Authors:  Brith Andresen; Marit Helen Andersen; Harald Lindberg; Gaute Døhlen; Erik Fosse
Journal:  BMJ Open       Date:  2014-07-29       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.